NYMX Nymox Pharmaceutical Corp

Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that Paul Averback, MD, DABP, President and Chief Executive Officer of Nymox, will be providing a corporate summary and presentation regarding the Company's ongoing clinical program for NX-1207 at the Jefferies 2013 Global Healthcare Conference in New York City on June 6, 2013 at 3:00 p.m. EDT.

Nymox's lead drug candidate, NX-1207, is currently in late stage Phase 3 trials for benign prostatic hyperplasia (BPH) and Phase 2 for localized prostate cancer. NX-1207 is a first-in-class patented drug that is injected into the sector of prostate to be treated by a urologist in a clinic setting. The injection procedure does not require catheterization, anesthesia, or sedation, takes only a few minutes and involves little or no pain or discomfort to the patient. In multi-center U.S. clinical trials for BPH to date, a single dose of NX-1207 has been found to produce on average symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs. Follow-up studies have shown evidence of long lasting benefit with a significant proportion of men who received a single dose reporting improvement in BPH symptoms without other treatments for up to 7½ years.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

CONTACT: Brian Doyle
         Nymox Pharmaceutical Corporation
         1-800-93NYMOX
         www.nymox.com